Price
No data yet.
Social Signal Score
Revenue
$36.25M+9505.37%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Philippe Jacques Wolgen
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 100
- Beta
- 0.61
- Country
- AU
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 17.09
Financials
Revenue
$36.25M+9505.4%Net Income
$10.25MEBITDA
$11.25MFree Cash Flow
$12.15MEPS (diluted)
$0.21Shares Outstanding (diluted)
50.62M+201.8%Operating Expenses
$9.62MCash & Debt
$232.77MReturn of Capital
$2.46MDividend per Share
$0.03Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $95.02M | $36.17M | $0.72 |
| 2024 | $88.18M | $35.64M | $0.72 |
| 2023 | $78.32M | $30.60M | $0.62 |
| 2022 | $65.72M | $20.88M | $0.42 |
| 2021 | $47.98M | $24.73M | $0.50 |
| 2020 | $32.57M | $16.65M | $0.31 |
| 2019 | $31.05M | $18.13M | $0.38 |
| 2018 | $25.49M | $13.22M | $0.28 |
| 2017 | $16.77M | $7.18M | $0.15 |
| 2016 | $6.82M | $-3.12M | $-0.07 |
| 2015 | $3.32M | $-10.40M | $-0.24 |
| 2014 | $2.66M | $-5.53M | $-0.14 |
| 2013 | $1.55M | $-6.80M | $-0.19 |
| 2012 | $722.8K | $-9.77M | $-0.32 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $1.06
- Implied price
- $14.86
- Return from $6.74
- 17.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $7.39 — today's price is already 8.8% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 10 | 12 | 14 | 16 | 18 |
|---|---|---|---|---|---|
| -2.0% | -0.6% | 3.1% | 6.3% | 9.2% | 11.8% |
| 3.0% | 4.4% | 8.3% | 11.7% | 14.7% | 17.5% |
| 8.0% | 9.5% | 13.6% | 17.1% | 20.3% | 23.2% |
| 13.0% | 14.6% | 18.8% | 22.6% | 25.9% | 28.9% |
| 18.0% | 19.6% | 24.1% | 28.0% | 31.4% | 34.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsglobenewswire.com·5h ago·Neutral
A decade of profitability provides foundation for CLINUVEL's U.S. expansion CLINUVEL PHARMACEUTICALS LTD announced its tenth consecutive annual profit and further rise in free cash in the financial year ended 30 June 2026 (FY2026).
View source ↗
Earnings
Tue, Sep 1(in 5 days)
Consensus estimate $0.32 per share
Typical surprise -2.6% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Feb 25$0.15 vs $0.20miss
- Thu, Aug 21$0.29 vs $0.18beat
- Wed, Feb 26$0.17 vs $0.14beat
- Wed, Aug 28$0.33 vs $0.30beat
- Thu, Feb 22$0.14 vs $0.17miss
- Fri, Jun 30$0.25 vs $0.25miss
Estimates and results for CLVLY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.